NDLI: "Targeted Therapy with Monoclonal Antibodies: The New Generation of Pharmaceuticals"

Content Provider	IEEE Xplore Digital Library
Author	Goldenberg, David M.
Copyright Year	2006
Description	Author affiliation: President, Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey; Chairman, Founder, Immunomedics, Inc., Morris Plains, New Jersey (Goldenberg, David M.)
Abstract	The last decade has witnessed a revolution in pharmaceutical sciences and commercial products with the introduction and intensification of biological products. Foremost has been the development and commercialization of antibodies, particularly for the therapy of cancer, with 8 such products already approved in the USA and hundreds of product candidates in various stages of clinical development. Although monoclonal antibodies have been pursued as new commercial candidates for about 30 years, advances in antibody engineering were required to de-immunize them for repeated human use, and when used as targeting agents, various constructs with isotopes, drug, and toxins have been developed and commercialized. As new targets become identified, the diverse antibody products are gaining in attention as prospective new therapeutics even beyond cancer, such as in the therapy of autoimmune, infectious, and neurodegenerative diseases. Not only are new antibody constructs of multifunctional nature being developed for enhanced potency, but new delivery systems involving methods of separating the targeting moiety from the effector molecules (radionuclided, drugs, toxins, cytokines), such as in so-called pretargeting methods, are under development. These advances have resulted in the concept of targeted disease therapy, attended by a better safety profile for this new class of pharmaceuticals, and are being used increasingly in combination with conventional cytotoxic drugs approved for the therapy of cancer and immune diseases. These disease-targeting antibodies, however, should soon decrease the dependence on traditional cytotoxic drugs by targeting such agents more selectively as immunoconjugates, especially with pretargeting technologies.
Sponsorship	IEEE EMB
Starting Page	9
Ending Page	10
File Size	104151
Page Count	2
File Format	PDF
ISBN	1424400325
ISSN	1557170X
DOI	10.1109/IEMBS.2006.259776
Language	English
Publisher	Institute of Electrical and Electronics Engineers, Inc. (IEEE)
Publisher Date	2006-08-30
Publisher Place	USA
Access Restriction	Subscribed
Rights Holder	Institute of Electrical and Electronics Engineers, Inc. (IEEE)
Subject Keyword	Medical treatment Pharmaceuticals Drugs Cancer Diseases Commercialization Immune system Biology Humans Isotopes
Content Type	Text
Resource Type	Article
Subject	Signal Processing Biomedical Engineering Health Informatics Computer Vision and Pattern Recognition

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Connectivity analysis of EEG under drug therapy

Nanoparticle enhanced thermal therapies

Nanotechnology based targeted drug delivery

Innovative Healthcare systems on their way to the market: How to cope with commercialization barriers

An image guided treatment platform for prostate cancer photodynamic therapy

Transorbital Endoscopic Image Guidance

ARhT: A portable Hand therapy system

Photochemical approach of photodynamic therapy applied to skin

Aptamer-NASBA LOC as a prospective tool for systemic therapy of cancer: Quantitative detection on signaling molecular profiling

"Targeted Therapy with Monoclonal Antibodies: The New Generation of Pharmaceuticals"

Similar Documents

Connectivity analysis of EEG under drug therapy

Nanoparticle enhanced thermal therapies

Nanotechnology based targeted drug delivery

Innovative Healthcare systems on their way to the market: How to cope with commercialization barriers

An image guided treatment platform for prostate cancer photodynamic therapy

Transorbital Endoscopic Image Guidance

ARhT: A portable Hand therapy system

Photochemical approach of photodynamic therapy applied to skin

Aptamer-NASBA LOC as a prospective tool for systemic therapy of cancer: Quantitative detection on signaling molecular profiling

"Targeted Therapy with Monoclonal Antibodies: The New Generation of Pharmaceuticals"